Pyrotinib plus epirubicin and cyclophosphamide followed by docetaxel and trastuzumab as neoadjuvant therapy for HER2-positive early breast cancer: A multicenter non-randomized phase II study

Résumé fourni par la source

Dual HER2 blockade combined with chemotherapy is the standard neoadjuvant approach for HER2-positive early breast cancer. Pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of a pyrotinib-based neoadjuvant regimen in patients with HER2-positive early breast cancer. This multicenter, phase II prospective study evaluated neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel plus trastuzumab (ACPy-THPy). A concurrent prospective cohort receiving standard docetaxel, carboplatin, trastuzumab, and pertuzumab (TCbHP) served as a real-world comparator. Propensity score matching (PSM) was applied to reduce baseline imbalances. The primary endpoint was pathological complete response (pCR). A total of 249 patients were included (ACPy-THPy, n = 120; TCbHP, n = 129). After 1:1 PSM (n = 83 per group), baseline characteristics were well balanced between groups. Before PSM, the pCR rate was numerically higher with ACPy-THPy than with TCbHP (65.0% vs. 55.0%, P = 0.109), with a significantly higher proportion of Miller-Payne grade 5 responses (70.8% vs. 58.9%, P = 0.003). After PSM, pCR rates remained numerically higher with ACPy-THPy (63.9% vs. 56.6%, P = 0.341), while Miller-Payne grade 5 responses were significantly more frequent (69.9% vs. 57.8%, P = 0.011). Objective response rates were comparable before (88.3% vs. 89.9%) and after matching (88.0% vs. 90.4%). With a median follow-up of 35.5 months, 2- and 3-year invasive disease-free survival rates were 97.3% and 95.2% in the ACPy-THPy group, compared with 94.4% and 92.5% in the TCbHP group. Diarrhea was more frequent with ACPy-THPy, with grade ≥3 events reported in 17.5%, but was clinically manageable. ACPy-THPy demonstrated promising pathological response rates and manageable toxicity in patients with HER2-positive early breast cancer. These findings support the feasibility of this pyrotinib-based neoadjuvant strategy and warrant further evaluation in randomized studies. The trial was prospectively registered with ClinicalTrials.gov (NCT04290793) on March 2, 2020.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.